|
gptkbp:instanceOf
|
gptkb:antibiotic
|
|
gptkbp:affiliatedWith
|
rifamycins
|
|
gptkbp:alsoKnownAs
|
gptkb:rifampin
|
|
gptkbp:approvalYear
|
1971
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:J04AB02
|
|
gptkbp:chemicalFormula
|
C43H58N4O12
|
|
gptkbp:combinationTherapy
|
gptkb:isoniazid
gptkb:ethambutol
gptkb:pyrazinamide
streptomycin
|
|
gptkbp:contraindication
|
hypersensitivity to rifamycins
|
|
gptkbp:discoveredBy
|
gptkb:Piero_Sensi
Grazia Timbal
|
|
gptkbp:discoveredIn
|
1965
|
|
gptkbp:drugInteraction
|
gptkb:warfarin
anticonvulsants
protease inhibitors
oral contraceptives
|
|
gptkbp:eliminationHalfLife
|
3-5 hours
|
|
gptkbp:excretion
|
urine
bile
|
|
gptkbp:firstSynthesized
|
1965
|
|
gptkbp:inducedBy
|
gptkb:cytochrome_P450_enzymes
|
|
gptkbp:lactationUse
|
caution advised
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Pfizer
gptkb:Sanofi
gptkb:Sandoz
|
|
gptkbp:mechanismOfAction
|
inhibits bacterial DNA-dependent RNA polymerase
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
822.94 g/mol
|
|
gptkbp:origin
|
gptkb:Streptomyces_mediterranei
|
|
gptkbp:overdoseSymptoms
|
nausea
vomiting
jaundice
unconsciousness
|
|
gptkbp:pregnancyCategory
|
C (US)
use only if clearly needed
|
|
gptkbp:riskOfResistance
|
high if used as monotherapy
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
rash
hepatotoxicity
gastrointestinal upset
flu-like syndrome
orange-red discoloration of body fluids
|
|
gptkbp:usedFor
|
gptkb:Staphylococcus_aureus_infections
tuberculosis
brucellosis
leprosy
Legionnaires' disease
meningococcal prophylaxis
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:RIF
gptkb:D014244
gptkb:Roussel_Works
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Rifampicin
|